Quiz for Clinicians – GLP-1 Safety and Coverage in Older Adults
Reviewed by: HU Medical Review Board | Last reviewed: August 2026 | Last updated: August 2026
Editor's Note: The Medicare GLP-1 Bridge is an evolving federal demonstration, currently authorized through December 31, 2027. The Part D portion of the successor Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) Model has been delayed and no replacement has been finalized. This information is subject to change based on upcoming CMS guidance and federal rulemaking.
Six weeks into the Medicare GLP-1 Bridge, the practical questions have shifted from whether a patient qualifies to how therapy is managed safely across a full year of care – and the coverage horizon itself moved in April. These 5 questions cover procedural planning, monitoring what is and is not indicated, and what the demonstration actually guarantees.
Clinical Challenge
A patient on a stable maintenance dose of weekly incretin therapy, without gastrointestinal symptoms, is scheduled for an elective colonoscopy. What does current multisociety guidance support?
Clinical Challenge
Through what date is the Medicare GLP-1 Bridge demonstration currently authorized?
Clinical Challenge
A patient 5 months into incretin therapy, with a 10 percent reduction in body weight, reports new right upper quadrant pain after meals. Which consideration is most relevant?
Clinical Challenge
In an asymptomatic patient on incretin therapy, which monitoring is of uncertain value?
Clinical Challenge
What does the largest randomized evidence to date show about cognitive outcomes with this drug class?